Shire shopping

Given a two-year buying spree by Shire plc (LSE:SHP; NASDAQ:SHPG), it comes as little surprise the company is mentioned in virtually every rumor relating to a biotech takeout in the rare disease and ophthalmology spaces, even if its cash hoard has dwindled as a result of its deal flow.